Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings, Inc. (HIND)
Company Research
Source: Business Wire
(Quarter Ended September 30, 2025)Completed a streamlined Nasdaq listing, with a 100% common stock capital structureDelivered encouraging interim Phase 2 results for VT-1953 in treating symptoms of malignant fungating wounds, in line with expectations.Disciplined, cost-efficient operations as Vyome burned less cash than expected, giving the company a cash runway expected to extend through 2026, inclusive of clinical trials.Added a new CTO and SVP of Clinical Development, bringing Big Pharma backgrounds, deep drug-development expertise, and experience across multiple FDA-approved therapies.Launched AI strategy with the acquisition of MIT startup Oculo CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc., (“Vyome”) (NASDAQ: HIND), a next-generation inflammation-focused company leveraging the US–India innovation corridor, today announced its financial results and a series of corporate and clinical milestones following its successful listing on Nasdaq.This quarter marks Vyome’s firs
Show less
Read more
Impact Snapshot
Event Time:
HIND
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIND alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIND alerts
High impacting Vyome Holdings, Inc. news events
Weekly update
A roundup of the hottest topics
HIND
News
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program [Yahoo! Finance]Yahoo! Finance
- Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW ProgramBusiness Wire
- Vyome (NASDAQ:HIND) is now covered by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>. They set a "sell (e-)" rating on the stock.MarketBeat
HIND
Sec Filings
- 11/26/25 - Form 424B3
- 11/19/25 - Form 8-K
- 11/19/25 - Form 4
- HIND's page on the SEC website